Key Highlights

  • The third-quarter net loss was USD 18.75 million versus USD 20.83 million a year earlier, as a USD 6.14 million gain on sale of strategic investments offset a wider operating loss of USD 23.30 million.
  • On November 9, 2026 the company closed an offering of 17,250,000 shares at USD 5.00 each, with net proceeds of about USD 80.5 million, including the underwriters' full option.
  • Cash, equivalents and marketable securities were USD 101.9 million on September 30, 2026, before the offering, and management said its budget funds operations through 2028.
  • Enrollment in the BACKBEAT hypertension trial finished with 349 randomized patients at 92 sites in 15 countries, and primary endpoint data are planned for Heart Rhythm 2027 in May.

Wider Operating Loss Masked by a USD 6.14 Million Investment Gain

Orchestra BioMed (NASDAQ:OBIO) filed its Quarterly Report for the period ended September 30, 2026 on November 10, 2026. It develops medical devices through partnerships with large device makers, led by AVIM Therapy for hypertension and the Virtue sirolimus balloon for artery disease. Revenue fell to USD 0.09 million from USD 0.86 million, because the former Terumo Partnership revenue ended and product sales slipped. Research and Development expense rose 26% to USD 17.7 million on trial work, while selling, general and administrative expense fell 21% to USD 5.6 million. Net interest expense rose to USD 2.46 million from USD 0.52 million, and the nine-month net loss was USD 63.2 million against USD 58.9 million.

USD 80.5 Million Offering Adds to a USD 101.9 Million Cash Base

The offering closed on November 9, 2026, one day before the filing. At the USD 5.00 price, 17,250,000 new shares dilute existing holders, but the company said the proceeds extend its cash position beyond the USD 101.9 million held at quarter end. The filing says current cash and securities are sufficient through 2028 under its internal budget, while warning that estimates may change and that more Capital may be needed earlier. An at-the-market sales agreement still allows up to USD 86.2 million of share sales. The accumulated Deficit is USD 425.8 million, and the filing says future viability depends on raising capital.

BACKBEAT Data in May 2027 and Virtue Trial Enrollment by End of 2027

Assuming the primary endpoints are met, the company and its partner Medtronic plan to present BACKBEAT results as a late-breaking presentation at Heart Rhythm 2027 in May, after which Medtronic is expected to file for approval. The Virtue trial compares the device head-to-head with a paclitaxel-coated balloon and is expected to enroll 740 patients in the United States by the end of 2027, though the company cannot assure that timing. In November 2026, three-year results from a pilot study showed a target lesion failure rate of 14.3%. A company R&D Day was scheduled for November 12, 2026. Risks include trial failure, delayed enrollment and partner decisions.

Where Things Stand

Possibly, though the filing hedges. Orchestra BioMed (NASDAQ:OBIO) reported USD 101.9 million of cash and securities and then closed an offering with about USD 80.5 million of net proceeds, while its budget points to funding through 2028. Against that, quarterly operating losses of USD 23.30 million are rising with trial spending, and the net loss was cushioned by a one-off investment gain. Its value rests on BACKBEAT and Virtue trial results. Next markers are the May 2027 data presentation, the R&D Day and enrollment progress toward the end of 2027.